Skip to main content

Recombinant Human/Mouse Wnt-5a Biotinylated Protein

R&D Systems, part of Bio-Techne | Catalog # BT645

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
Carrier Free
BT645-010/CF

Catalog #
Availability
Size / Price
Qty
With Carrier
BT645-010

Key Product Details

Source

CHO

Accession #

Conjugate

Biotin

Applications

Bioactivity

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived Wnt-5a protein
Gln38-Lys380

Purity

>80%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Asn44 & No results obtained: Gln38 predicted

Predicted Molecular Mass

38 kDa

Activity

Measured by its binding ability in a functional ELISA.
In a 100 µL reaction mixture containing biotinylated Recombinant Mouse Wnt-5a at 50 ng/mL and Recombinant Human Frizzled‑5 Fc Chimera (Catalog # 1617-FZC) dilutions, the concentration of Recombinant Human Frizzled‑5 Fc Chimera that produces 50% of the maximal binding response is 2-20 ng/mL.

Scientific Data Images for Recombinant Human/Mouse Wnt-5a Biotinylated Protein

Recombinant Human/Mouse Wnt-5a Biotinylated Protein Binding Activity

Recombinant Human/Mouse Wnt-5a Biotinylated Protein Binding Activity

Recombinant Biotinylated Mouse Wnt-5a (Catalog # BT645) binds to Recombinant Human Frizzled-5 Fc Chimera (Catalog # 1617-FZC) with an ED50 of 2-20 ng/mL.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: BT645
Formulation Lyophilized from a 0.2 μm filtered solution in PBS, EDTA, CHAPS and Trehalose with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
Carrier Free: BT645/CF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS, EDTA and CHAPS with Trehalose.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Background: Wnt-5a

Wnt-5a is a 44‑50 kDa member of the Wnt family of proteins (1‑6). Based on its activity towards C57Mg mammary epithelium, it is classified as a nontransforming Wnt. Human Wnt‑5a is synthesized as a 380 amino acid (aa) precursor that contains a 37 aa signal sequence, a 25 aa prosegment, and a 319 aa mature region (1, 2, 3). The mature region has 24 cysteine residues that form multiple intrachain disulfide bonds, plus four N‑linked glycosylation sites that are utilized for proper secretion (3, 5, 7). There is also a palmitate adduct at Cys104 that is essential for activity, and a potential palmitoleic acid modification at Ser244 that may also contribute to secretion (7‑9). One alternative start site is reported at Met16. Over aa 38‑380, human and mouse Wnt‑5a are identical in amino acid sequence (1, 10). Cells known to express Wnt‑5a include brainstem astrocytes (11), mammary epithelium (12), CD34+ primitive progenitor stem cells (13), chondrocytes (14), CD34- pericytes and vascular smooth muscle cells (15), plus mesenchymal cells at various sites (16, 17). There are multiple receptors for Wnt‑5a. These include Fzd-1, -2,
-3, -4, -5, and -7 (3, 18‑22), Ror2 (3), LRP6 (23), Ryk (24) and sFRP1 (25). All these molecules function within the context of a larger number of “co‑factors” that regulate signaling by the Wnts. Initially, it was suggested that there were three pathways for Wnt signaling; a beta-catenin-mediated canonical pathway, and two noncanonical pathways described as the Wnt/JNK (PCP) pathway and the Wnt/Ca++ pathway (26, 27). And it was assumed that various Wnts could be accommodated by these classifications. At present, it is now recognized that individual Wnts, through various combinations of receptor complex subunits, can have diverse effects, perhaps even within the same cell (3, 6, 27). Further complexity is introduced by the fact that Xenopus Wnt‑5a and Wnt‑11 are known to form bioactive heterodimers following Tyr sulfation (28). Thus, predicting the activity of Wnt‑5a, or any other Wnt, on any cell type will require substantial insight into the interaction between all the extracellular, cell surface and intracellular components of the Wnt signaling system.

References

  1. Clark, C.C. et al. (1993) Genomics 18:249.
  2. LeJeune, S. et al. (1995) Clin. Cancer Res. 1:215.
  3. Mikels, A.J. & R. Nusse (2006) PLoS Biol. 4:e115.
  4. Nishita, M. et al. (2010) Trends Cell Biol. 20:346.
  5. Mikels, A.J. & R. Nusse (2006) Oncogene 25:7461.
  6. van Amerongen, R. & R. Nusse (2009) Development 136:3205.
  7. Kurayoshi, M. et al. (2007) Biochem. J. 402:515.
  8. Takada, R. et al. (2006) Dev. Cell 11:791.
  9. Port, F. & K. Basler (2010) Traffic May 3. [Epub ahead of print].
  10. Gavin, B.J. et al. (1990) Genes Dev. 4:2319.
  11. Castelo-Branco, G. et al. (2006) Mol. Cell. Neurosci. 31:251.
  12. Jonsson, M. et al. (1998) Br. J. Cancer 78:430.
  13. van Den Berg, D.J. et al. (1998) Blood 92:3189.
  14. Kruger, C. & C. Kappen (2010) PLoS One 5:e8978.
  15. Lin, G. et al. (2008) Stem Cells Dev. 17:1053.
  16. Lickert, H. et al. (2001) Mech. Dev. 105:181.
  17. Danielson, K.G. et al. (1995) J. Biol. Chem. 270:31225.
  18. Gazit, A. et al. (1999) Oncogene 18:5959.
  19. Bazhin, A. V. et al. (2010) Cell. Mol. Life Sci. 67:817.
  20. Kawasaki, A. et al. (2007) Cell. Signal. 19:2498.
  21. Blumenthal, A. et al. (2006) Blood 108:965.
  22. Umbhauer, M. et al. (2000) EMBO J. 19:4944.
  23. Bryja, V. et al. (2009) Mol. Biol. Cell 20:924.
  24. Keeble, T.R. et al. (2006) J. Neurosci. 26:5840.
  25. Lin, K. et al. (1997) Proc. Natl. Acad. Sci. USA 94:11196.
  26. Rao, T.P. & M. Kuhl (2010) Circ. Res. 106:1798.
  27. McDonald, S.L. & A. Silver (2009) Br. J. Cancer 101:209.
  28. Cha, S-W. et al. (2009) Curr. Biol. 19:1573.

Long Name

Wingless-type MMTV Integration Site Family, Member 5a

Alternate Names

Wnt5a

Entrez Gene IDs

7474 (Human); 22418 (Mouse)

Gene Symbol

WNT5A

UniProt

Additional Wnt-5a Products

Product Documents for Recombinant Human/Mouse Wnt-5a Biotinylated Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human/Mouse Wnt-5a Biotinylated Protein

For research use only

Loading...
Loading...
Loading...